Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China (Z.Y., J.C., R.Z., T.L., Z.N., C.Z., Y.W., X.S.).
Center for Intelligent Medicine Research, Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University, China (Z.Y., J.C., R.Z., T.L., X.S.).
Circulation. 2022 May 3;145(18):1398-1411. doi: 10.1161/CIRCULATIONAHA.121.057888. Epub 2022 Apr 7.
SARS-CoV-2, the causal agent of COVID-19, enters human cells using the ACE2 (angiotensin-converting enzyme 2) protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart and respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biological systems. However, the genetic basis of the ACE2 protein levels is not well understood.
We have conducted the largest genome-wide association meta-analysis of plasma ACE2 levels in >28 000 individuals of the SCALLOP Consortium (Systematic and Combined Analysis of Olink Proteins). We summarize the cross-sectional epidemiological correlates of circulating ACE2. Using the summary statistics-based high-definition likelihood method, we estimate relevant genetic correlations with cardiometabolic phenotypes, COVID-19, and other human complex traits and diseases. We perform causal inference of soluble ACE2 on vascular disease outcomes and COVID-19 severity using mendelian randomization. We also perform in silico functional analysis by integrating with other types of omics data.
We identified 10 loci, including 8 novel, capturing 30% of the heritability of the protein. We detected that plasma ACE2 was genetically correlated with vascular diseases, severe COVID-19, and a wide range of human complex diseases and medications. An X-chromosome cis-protein quantitative trait loci-based mendelian randomization analysis suggested a causal effect of elevated ACE2 levels on COVID-19 severity (odds ratio, 1.63 [95% CI, 1.10-2.42]; =0.01), hospitalization (odds ratio, 1.52 [95% CI, 1.05-2.21]; =0.03), and infection (odds ratio, 1.60 [95% CI, 1.08-2.37]; =0.02). Tissue- and cell type-specific transcriptomic and epigenomic analysis revealed that the ACE2 regulatory variants were enriched for DNA methylation sites in blood immune cells.
Human plasma ACE2 shares a genetic basis with cardiovascular disease, COVID-19, and other related diseases. The genetic architecture of the ACE2 protein is mapped, providing a useful resource for further biological and clinical studies on this coronavirus receptor.
导致 COVID-19 的 SARS-CoV-2 病毒通过 ACE2(血管紧张素转换酶 2)蛋白作为受体进入人体细胞。因此,ACE2 是冠状病毒感染和治疗的关键。ACE2 在心脏和呼吸及胃肠道中高度表达,在心血管等生物系统中发挥重要调节作用。然而,ACE2 蛋白水平的遗传基础尚不清楚。
我们对来自 SCALLOP 联盟(基于 Olink 蛋白的系统和综合分析)的 28000 多名个体进行了 ACE2 血浆水平的最大全基因组关联荟萃分析。我们总结了循环 ACE2 的横断面流行病学相关性。使用基于汇总统计信息的高分辨率似然法,我们估计了与心血管代谢表型、COVID-19 及其他人类复杂特征和疾病的相关遗传相关性。我们使用孟德尔随机化方法对血管疾病结局和 COVID-19 严重程度进行可溶性 ACE2 的因果推断。我们还通过整合其他类型的组学数据进行了计算机模拟功能分析。
我们确定了 10 个位点,包括 8 个新位点,捕获了该蛋白 30%的遗传率。我们发现,血浆 ACE2 与血管疾病、严重 COVID-19 以及广泛的人类复杂疾病和药物治疗具有遗传相关性。基于 X 染色体顺式蛋白数量性状基因座的孟德尔随机化分析表明,ACE2 水平升高与 COVID-19 严重程度(比值比,1.63 [95%CI,1.10-2.42];=0.01)、住院(比值比,1.52 [95%CI,1.05-2.21];=0.03)和感染(比值比,1.60 [95%CI,1.08-2.37];=0.02)有关。组织和细胞类型特异性转录组和表观基因组分析显示,ACE2 调节变异在血液免疫细胞中富含 DNA 甲基化位点。
人类血浆 ACE2 与心血管疾病、COVID-19 及其他相关疾病具有共同的遗传基础。ACE2 蛋白的遗传结构已被定位,为进一步研究该冠状病毒受体的生物学和临床特征提供了有用的资源。